COMMUNIQUÉS West-GlobeNewswire

Grey Matters Takes Delivery of the First Brain Dedicated PET Scanning System for its Flagship NovaScan Neuroimaging Clinic in Florida
06/07/2026
VANCOUVER, British Columbia, July 06, 2026 (GLOBE NEWSWIRE) -- Grey Matters Health Inc. (the “Company” or “Grey Matters”) (CSE: GREY) (FRANKFURT: AGW0) (OTC: AGNPF), a Canadian healthcare company, is pleased to announce [...]
LENZ Therapeutics Announces Launch of New Telehealth Prescribing Option to Accelerate Patient Access to VIZZ® for the Treatment of Presbyopia
06/07/2026
VIZZ is now available for those who qualify through a convenient telehealth platform in addition to existing access through eye care professionals Telehealth offers patients the convenience of an integrated online [...]
LIXTE Completes Corporate Name Change to NOMAD Power Solutions, Inc.; To Begin Trading Under New Nasdaq Symbol NMAD
06/07/2026
-- New Corporate Identity Reflects Strategic Transition into AI Energy Infrastructure Equipment & Services Sector Following Acquisition of NOMAD Transportable Power Systems -- BOCA RATON, Fla., July 06, 2026 (GLOBE [...]
Immuron Advances IMM-529 (Clostridioides difficile infection) Partnering Strategy
06/07/2026
Key Points Immuron Engages Pullan Consulting to Advance IMM-529 Partnering Strategy Immuron is seeking a partner to support clinical development through regulatory approval and commercialization Immuron has U.S. Food [...]
NovMetaPharma and the FSHD Canada Foundation Establish Collaboration to Advance Cyclo-Z, a First-in-Class Oral Muscle-Preserving Therapy, into Facioscapulohumeral Muscular Dystrophy
06/07/2026
Disease-foundation-funded program extends NovMetaPharma’s muscle-preservation platform into a serious neuromuscular disease with no approved disease-modifying treatment; collaboration provides non-dilutive capital to [...]
Invivyd Announces Receipt of Twelve Months’ Advanced Notice of Emergency Use Authorization (EUA) Termination for PEMGARDA® and Provides an Update on Next Steps with the U.S. FDA
06/07/2026
U.S. Department of Health and Human Services (HHS) announced advanced Notice of Termination of the COVID-19 EUA declaration, effective June 29, 2027 Consequently, Invivyd received from the U.S. Food and Drug [...]
Can-Fite Achieves Key Pivotal Phase 3 Psoriasis Milestone with Completion of Patient Enrolment for the Interim Analysis: Data Expected Q4 2026/Q1 2027
06/07/2026
Interim analysis to be conducted under an FDA- and EMA-agreed protocol Ramat Gan, Israel, July 06, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology [...]
Moleculin CEO, Walter Klemp, Highlights Positive Preliminary MIRACLE Trial Results in Virtual Investor "What This Means" Segment
06/07/2026
Access the segment here HOUSTON, July 06, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that Walter Klemp, Chairman and Chief Executive Officer of [...]
Pharvaris Announces FDA Acceptance of New Drug Application for Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema Attacks
06/07/2026
If approved, deucrictibant will be the first oral bradykinin B2 receptor antagonist to treat HAE attacks NDA includes positive data from successful clinical program demonstrating rapid relief and sustained response to [...]
BiomX: Subsidiary Zorronet Commences Installation and Operation of AI-Powered Detection Systems Under Israel Railways Agreement
06/07/2026
NETANYA, Israel, July 06, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), announced today following its April 16, 2026 announcement that its wholly-owned subsidiary Zorronet has [...]
Neuronetics to Participate in a Panel Discussion at B. Riley Securities' Mind, Muscle & Vision Summit on July 16, 2026
06/07/2026
MALVERN, Pa., July 06, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a leader in interventional mental health that combines its NeuroStar® TMS technology with direct patient care through the Greenbrook [...]
Vivos Inc. (OTCQB: RDGL) Receives U.S. FDA Approval for Investigational Device Exemption (IDE) to Initiate Human Clinical Feasibility Study for RadioGel® Precision Radionuclide Therapy™
06/07/2026
Kennewick, WA, July 06, 2026 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a medical device company pioneering Precision Radionuclide Therapy ™ (PRnT) for the treatment of cancerous tumors, is pleased to announce that [...]
Nephros Announces Inclusion in the Russell Microcap® Index
06/07/2026
SOUTH ORANGE, N.J., July 06, 2026 (GLOBE NEWSWIRE) -- Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced that the [...]
Amplia Announces Changes to Board’s Leadership Roles
06/07/2026
Melbourne, Australia, July 06, 2026 (GLOBE NEWSWIRE) -- Amplia Therapeutics Limited (ASX:ATX, OTCQB:INNMF), (“Amplia” or the “Company”), announces Board changes further to a Board renewal and succession plan. Dr Warwick [...]
Catheter Precision, Inc. Announces Issuance of Two Key Patents
06/07/2026
New Intellectual Property Covers VIVO Technology and Cardionomix Heart Failure Technology FORT MILL, SC, July 06, 2026 (GLOBE NEWSWIRE) -- Catheter Precision Inc., (VTAK: NYSE/American), a US based medical device [...]
Novo Nordisk A/S - share repurchase programme
06/07/2026
Bagsværd, Denmark, 6 July 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) [...]
Cannabix Technologies Announces Detection of Cocaine and Benzoylecgonine in Human Breath
06/07/2026
VANCOUVER, British Columbia, July 06, 2026 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTCID: BLOZF) (Frankfurt: 8CT) (the “Company” or “Cannabix”) developer of marijuana and alcohol breath testing [...]
Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting
06/07/2026
SAN DIEGO, July 06, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)- [...]
AtaiBeckley Doses Last Patient in VLS-01 Phase 2b TRD Study; Plans Phase 3 in Major Depressive Disorder
06/07/2026
156 patients randomized in multi-center, double-blind, placebo-controlled Phase 2b Elumina trial; topline data anticipated in Q4 2026 (ClinicalTrials.gov: NCT06524830 ) AtaiBeckley plans to advance VLS-01 into major [...]

Pages